SEC Form 4 · accession 0001104659-18-008061
AGILE THERAPEUTICS INC · AGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Alfred Altomari
Officer — Chief Executive Officer · Director
Period of report
Feb 8, 2018
Accepted (ET)
Feb 9, 2018 · 4:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001261249
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2018 | M | 16,667 | — | A | 178,254 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Feb 8, 2018 | M | 16,667 | D | — | — | Common Stock | 16,667 | 35,314 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of common stock.
- F250,000 restricted stock units were granted on February 8, 2016 and vest as follows: 16,666 units vested and were delivered on the grant date, 16,667 units vested and were delivered on February 8, 2017, and 16,667 units vested and were delivered on February 8, 2018; The 35,314 remaining restricted stock units were granted on January 24, 2018 and will be fully vested and delivered on January 24, 2019.